DOMINGO FERNÁNDEZ VECILLA, MARY PAZ ROCHE MATHEUS, GOTZON IGLESIAS HIDALGO, ESTÍBALIZ UGALDE ZÁRRAGA, MIREN JOSEBE UNZAGA BARAÑANO, JOSÉ LUIS DÍAZ DE TUESTA DEL ARCO
Published: 16 May 2023
LETTER TO THE EDITOR
http://www.doi.org/10.37201/req/001.2023
Rev Esp Quimioter 2023; 36(4): 439-441 [Full-text PDF]
ALFREDO MALDONADO-BARRUECO, DAVID GRANDIOSO-VAS, JULIO GARCÍA-RODRÍGUEZ, INMACULADA QUILES-MELERO
Published: 15 May 2023
LETTER TO THE EDITOR
http://www.doi.org/10.37201/req/103.2022
Rev Esp Quimioter 2023; 36(3): 314-316 [Texto completo PDF]
CRISTIAN MATEO LEÓN, DIEGO GARCÍA MARTÍNEZ DE ARTOLA, BERTA PINO-CALM
Published: 8 May 2023
http://www.doi.org/10.37201/req/014.2023
Introduction. Mycoplasma genitalium (MG) is a recognized sexually transmitted pathogen. Increasing resistance to main lines of treatment (macrolides and quinolones) justifies a genetic study of mutations to improve cure rates.
Material and methods. A total of 8,508 samples from April 2018 to July 2022 were processed using AllplexTM STI Essential Assay. In MG positive cases 23S rRNA V domain, gyrA and parC genes were studied. Mutations detected were checked to assess their clinical significance and medical records were reviewed to obtain demographic and treatment information.
Results. Resistance study was performed on 92 samples (65 men and 27 women). In relation to the genotypic study, 28 patients presented mutations to macrolides (30.43%). Most common was A2059G (18.48%). For quinolones, 5 patients (5.43%) had clinically relevant mutations in parC gene. Of note was a patient with G295 mutation in gyrA associated with G248T in parC. Thirty subjects underwent a test of cure (TOC). Azithromycin was the most common empirical regimen and moxifloxacin the main alternative.
Conclusions. High rate of resistance in our environment evidences the need for targeted therapy by genotypic study of macrolide resistance, supported by the detection of mutations in parC and gyrA to predict quinolones susceptibility and the use of TOC to evaluate treatment response
Rev Esp Quimioter 2023; 36(4): 416-420 [Texto completo PDF]
AGUSTÍN JULIÁN-JIMÉNEZ, RAFAEL RUBIO-DÍAZ, JUAN GONZÁLEZ DEL CASTILLO, ERIC JORGE GARCÍA-LAMBERECHTS, ITZIAR HUARTE SANZ, CARMEN NAVARRO BUSTOS, FRANCISCO JAVIER CANDEL, PEDRO ÁNGEL DE SANTOS, RAÚL ALONSO AVILÉS EN NOMBRE DEL GRUPO INFURG-SEMES
Published: 8 May 2023
http://www.doi.org/10.37201/req/008.2023
Objectives. To evaluate lactate and the Quick Sepsis-Related Organ Failure Assessment (qSOFA) and compare their ability to predict 30-day mortality in patients treated for infection in emergency departments (ED).
Methods. Prospective multicenter observational cohort study. We enrolled a convenience sample of patients aged 18 years or older attended in 71 Spanish ED from October 1, 2019, to March 31, 2020. Each model’s predictive power was analyzed with the area under the receiver operating characteristic curve (AUC), and its values of sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative (NPV).
Results. A total of 4439 patients with a mean (SD) age of 18 years were studied; 2648 (59.7%) were men and 459 (10.3%) died within 30 days. For 30-day mortality, the AUC-COR obtained with the qSOFA = 1 model plus 2 mmol/l lactate was 0.66 (95% CI, 0.63-0.69) with Se: 68%, Es: 70% and NPV:92%, while qSOFA = 1 obtained AUC-COR of 0.52 (95% CI, 0.49-0.55) with a Se:42%, Es:64% and NPV:90%.
Conclusions. To predict 30-day mortality in patients presenting to the ED due to an episode of infection, the qSOFA =1 + lactate≥2 mmol/L model significantly improves the predictive power achieved individually by qSOFA1 and becomes very similar to qSOFA≥2.
Rev Esp Quimioter 2023; 36(4): 408-415 [Texto completo PDF]
JORDI REINA, ELISA GONZÁLEZ DE HERRERO
Published: 4 May 2023
LETTER TO THE EDITOR
http://www.doi.org/10.37201/req/003.2023
Rev Esp Quimioter 2023; 36(4): 442-443 [Texto completo PDF]
ADRIÁN RODRÍGUEZ-FERRERAS, IVAN MARAY, COVADONGA COYA-FERNÁNDEZ, MANUELA MARÍA OCTAVIO-BOCIGAS, MANUEL FELICÍSIMO FERNÁNDEZ-DEL RÍO, SUSANA CASARES-LÓPEZ, JESÚS RUIZ-SALAZAR
Published: 3 May 2023
LETTER TO THE EDITOR
http://www.doi.org/10.37201/req/140.2022
Rev Esp Quimioter 2023; 36(4): 429-431 [Full-text PDF]
CELIA GARCÍA-RIVERA, ISABEL ESCRIBANO, ESPERANZA MERINO, JUAN CARLOS RODRIGUEZ
Published: 3 May 2023
LETTER TO THE EDITOR
http://www.doi.org/10.37201/req/136.2022
Rev Esp Quimioter 2023; 36(4): 427-428 [Texto completo PDF]
DAVID SÁNCHEZ FABRA, TINA HERRERO JORDÁN, ALICIA ALDA LOZANO, VICTORIA DURO SUÁREZ, NURIA SAURA BLASCO, ISABEL TORRES COURCHOUD
Published: 3 May 2023
http://www.doi.org/10.37201/req/138.2022
Introduction. Home Hospitalization (HH) is an alternative hospitalization modality that can be very useful in times of health stress such as the COVID-19 pandemic. This paper includes the management of patients admitted with COVID-19 in HH in two county spanish hospitals for two years.
Methods. A descriptive, observational and retrospective study of all patients admitted at HH with a diagnosis of COVID-19 disease was carried out. Subsequently, further analysis was carried out to characterize the patients who died in HH or 30 days after discharge and another to compare the management between the first phase of the study (2020) and the second one (2021 and part of 2022).
Results. A total of 167 patients were recruited. A 52.1% moved to watch that the recovery continued compared to 40.7% in which it was done to watch that they did not worsen. The patients who died in HAD were older (mean 87.5 years), more comorbid and more likely to have do-not resucitate orders (DNR) in case of cardiac arrest (85%). In the second phase of the study, older patients, more comorbid patients and with a greater degree of DNR orders were admitted than those admitted throughout 2020.
Conclusions. HAD is a useful resource to increase the resilience of health systems in cases of stress such as the disease caused by COVID-19. The development and growth of existing units, as well as the creation of new ones where they do not exist, could be a basic tool for the medicine of the future.
Rev Esp Quimioter 2023; 36(4): 392-399 [Texto completo PDF]
CARLOS RISCO-RISCO, DIEGO MARTÍNEZ-URBISTONDO, RAFAEL SUÁREZ DEL VILLAR, LUIS AYERBE GARCÍA-MONZÓN, ALBERTO PÉREZ-RUBIO, JOSÉ BARBERÁN-LÓPEZ, DAVID ANDALUZ-OJEDA, PAULA VILLARES FERNÁNDEZ
Published: 29 April 2023
http://www.doi.org/10.37201/req/017.2023
Introduction. Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs).
Material and methods. Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine.
Results. Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose.
Conclusion. Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.
Rev Esp Quimioter 2023; 36(4): 400-407 [Full-text PDF]
AARON PUPLÀ BARTOLL, Mª DOLORES BELLÉS MEDALL, IGNACIO PÉREZ CATALÁN, CELIA ROIG MARTÍ, JULIA BODEGA AZUARA, MAYTE GIL CANDEL, VICENT ESTEVE LÓPEZ, RAÚL FERRANDO PIQUERES
Published: 28 April 2023
LETTER TO THE EDITOR
http://www.doi.org/10.37201/req/147.2022
Rev Esp Quimioter 2023; 36(4): 436-438 [Texto completo PDF]
